LDN (Low-Dose Naltrexone)

Off-label use of low-dose naltrexone (1.

Evidence Score

79/100

Developer

Bernard Bihari

Duration

Ongoing, improvements typically in 2-3 months

Steps

10 phases

Conditions

6 targeted

Protocol Overview

Off-label use of low-dose naltrexone (1.5-4.5mg) to modulate immune system and increase endorphins. Originally an opioid antagonist at high dose (50mg), low dose has paradoxical immune-boosting effects.

Conditions Treated

Multiple sclerosisCrohn's diseaseHashimoto'srheumatoid arthritisfibromyalgiacancer

Multiple Sclerosis →Crohn's Disease / Ulcerative Colitis (IBD) →Hashimoto's Thyroiditis →Rheumatoid Arthritis →Chronic Fatigue / Fibromyalgia →Cancer (Integrative Support) →

Key Resources

LDN Research Trust (ldnresearchtrust.org), "The LDN Book" edited by Linda Elsegood, research papers by Bihari, compounding pharmacy directory

Safety Profile

Contraindications & Risks

Cannot use with opioid medications (blocks effect), Crohn's with obstruction (temporary inflammation), pregnancy uncertain

Important Notes

Strong safety profile, inexpensive ($30-50/month), growing evidence base. Works by blocking opioid receptors temporarily, causing rebound endorphin increase and immune modulation. Many physicians now prescribe. Need compounding pharmacy. Off-label but increasingly accepted.

Find a Practitioner

Connect with practitioners experienced in this protocol.

Browse Practitioners

EvidenceModerate

Evidence Score79/100

Categoryautoimmune

DurationOngoing, improvements typically in 2-3 months

About Evidence Score

The Evidence Score rates the strength of clinical and scientific evidence behind this protocol. Higher scores indicate stronger research support. This is a research tool, not medical advice.

Educational purposes only. Some alternative protocols carry serious risks. Always consult qualified healthcare professionals before beginning any treatment.